FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington.	D.C.	20549

nington, D.C. 20549	OMB APPROVAL

- 1	_	_								
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

.(0). 0.	e instruction																		
Name and Address of Reporting Person* Chiniara Ellen					2. Issuer Name and Ticker or Trading Symbol <u>Kymera Therapeutics, Inc.</u> [KYMR]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner							
						-46		T		(1.4 4	L (D - : - 0 ()		$\overline{}$	1	belov	er (give title v)		Other (s below)	specify
(Last) (First) (Middle)						ate of E 06/202		rran	Isactio	on (iviont	h/Day/Year)			Chief Legal Officer					
C/O KYMERA THERAPEUTICS, INC.			01/	00/202															
500 NORTH BEACON STREET, 4TH FLOOR																			
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line) Form filed by One Reporting Person					
WATERTOWN MA 02472												1		•	•				
														Form filed by More than One Reporting Person					orting
(City)	(State)	(Zip)																
(- 5)																			
		Tabl	e I - I	Non-Deriva	itive	Secui	rities	Ac	quir	ed, Di	sposed c	of, or	Benefic	ially	Own	ed			
1. Title of S	Security (In	str. 3)		2. Transaction		2A. Deemed			3. 4. Securities Acquired (A) or				5. Amount of		6. Ownership		7. Nature		
Date (Month/Day/Ye			ear) Execution if any (Month/Day		· (Transaction Disp		isposed Of (D) (Instr. 3, 4 an		r. 3, 4 and	d 5) Securities Beneficially			Form: Direction (D) or		of Indirect Beneficial		
(montanzay)		8)						Ow		ed Following Ìnd		direct (I)	Ownership (Instr. 4)						
					Γ	Code	V A	mount	(A) or	Price		Transa	ransaction(s)		. 4)	(Instr. 4)			
										, , ,		(D)			(Instr. 3 and 4)				
Common	Stock			01/06/202	5 s ⁽¹⁾ 3,129 D \$41.		\$41.752	29 ⁽²⁾ 54,826 ⁽³⁾			D								
		т.	hla	II Doriveti	S	001141	ioo /	\		d Dia	seed of	or D	poficio	ulv. C)wood	-J			
		10	abie	ll - Derivati (e.g., pu							converti				JWIIE	u			
1. Title of 2. 3. Transaction 3						4.		5. Number				7. Title and		8. Price of				10.	11. Nature
				cution Date,				of Expiration Derivative (Month/I		oiration Donth/Day			unt of rities	Derivative Security		derivative Securities		Ownership Form:	of Indirect Beneficial
(Instr. 3) Price of (Month/Day/			onth/Day/Year)	8)	(Securities		es ` Unde			erlying		tr. 5)	5) Beneficially		Direct (D)	Ownership		
	Derivative Security					Acquired (A) or Disposed of (D)							rative rity (Instr.			Owned Following		or Indirect I) (Instr. 4)	(Instr. 4)
											3 and	14)			Reported Transaction	1/e) `			
					(Instr. 3,			istr. 3, 4						(Instr. 4)	1(3)				
					and 5)		5)				1								
													Amount						
											<u> </u>		Number						
					Code	ode V (A) (D		(D)	Date) Exercisable		Expiration Date	Title	of Shares						

Explanation of Responses:

- 1. Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.50 to \$41.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. This number includes 1,203 shares and 792 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024 and December 1, 2024, respectively.

/s/ Bruce Jacobs, as Attorneyin-Fact 01/06/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.